[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.79.216. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
Practice Gaps
February 2014

Preventing and Detecting Antibodies to Anti–Tumor Necrosis Factor AgentsGaps in Practice or in Evidence?

Author Affiliations
  • 1Department of Dermatology, University of Utah School of Medicine, Salt Lake City
JAMA Dermatol. 2014;150(2):136-137. doi:10.1001/jamadermatol.2013.8375

Although anti–tumor necrosis factor (TNF) agents are considered highly effective therapies for psoriasis, treatment failure is common. As highlighted in the study by Menting et al,1 primary failure is more frequent in the “real-world” setting compared with randomized clinical trials with adalimumab and is associated with formation of antidrug antibodies (ADAs) and low serum drug levels. This article further highlights the high frequency of ADA formation (50%) in patients not receiving concomitant methotrexate. These issues raise 2 questions: (1) should adalimumab be prescribed with methotrexate at the outset and (2) should ADA and trough drug levels be drawn when patients fail to respond to adalimumab to aid in the decision to escalate dose or switch therapy?

First Page Preview View Large
First page PDF preview
First page PDF preview
×